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Dysregulated hedgehog (HH) signaling has been found in numerous cancers, suggesting that therapeutic
targeting of this pathway may be useful versus a wide range of cancers. Basal cell carcinoma (BCC) is an
excellent model system for studying the influence of the HH pathway on carcinogenesis because aberrant
activation of HH signaling is crucial not only for the development of but also the maintenance of BCC.
Genetically engineered BCC mouse models provide one important tool for the study of the biology of human
BCCs and for evaluating therapeutic interventions, as these mice produce multiple genetically defined tumors
within a relatively short period of time. However, these models remain expensive and cumbersome to use for
large-scale preclinical drug testing. Here we report a method for growing allografts from murine BCC tumors in
NOD/SCID mice. These allografts develop faster and reproduce the histology, immunophenotypes, and
response to at least one anti-BCC drug of the parental autochthonous tumors from which they arise. Therefore,
the allograft model provides a practical model for (i) studying BCC carcinogenesis and (ii) initial preclinical
screening for anti-HH pathway and other anti-BCC drugs.
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INTRODUCTION
Basal cell carcinoma (BCC) is the most prevalent cancer in the
Western world, and its incidence is increasing worldwide. Most
BCCs occur sporadically, but patients with the basal cell nevus
(Gorlin) syndrome (OMIM #109400), are predisposed to
developing large numbers of BCCs. Mutational activation of
hedgehog (HH) signaling underlies both familial and sporadic
BCCs. Approximately 90% of sporadic BCCs have loss-of-
function mutations in patched 1 (Ptch1), and others have
activating mutations in the downstream smoothened (SMO)
gene (Epstein, 2008). Based on this knowledge, several murine
models have been developed in which the transgenic over-
expression of activators or the deletion of repressors drives skin
HH signaling. We have focused on the Ptch1 heterozygous
(Ptch1þ /) mouse, in which ionizing (IR) or UV radiation
produces multiple BCCs (Aszterbaum et al., 1999), thus
mimicking basal cell nevus (Gorlin) syndrome patients.
However, this and other autochthonous tumor models remain
cumbersome and expensive for initial in vivo preclinical testing
of anti-BCC agents. By contrast, the use of tumor allograft
models has been well established for many cancers, providing
many advantages for preclinical screening: shorter tumor
latency, a more predictable growth rate, and the production
of essentially identical tumor replicates.
Attempts to grow human BCCs as mouse xenografts met
with little success. Studies relying on nude mice gave low
percentages of tumor uptake and slow growth rates (Pawlowski
and Haberman, 1979; Grimwood et al., 1985). In some cases,
various degrees of differentiation occurred in tumor transplants
(Loning and Mackenzie, 1986; Stamp et al., 1988). Recent
studies using more severely immunocompromised models, i.e.
beige-nude or SCID-beige mice, moderately improved the
implantation efficiency (Grimwood and Tharp, 1991; Carlson
et al., 2002). However, it has not been determined whether
these xenografts resemble their parental BCC tumors in their
histology, immunophenotypes, and response to drug treatment.
Here we show that murine BCC cells transplanted with
Matrigel into NOD/SCID mice, a newer immunocompro-
mised mouse model, produce allografts that histologically
and immunophenotypically reproduce the parental auto-
chthonous tumors from which they were derived. To our
knowledge, such BCC allografts have not been reported
previously. Furthermore, we demonstrate that allografts
respond to tazarotene treatment in a manner similar to that
of autochtonous tumors, indicating that the allografts may
indeed be a useful anti-BCC agent evaluation system.
RESULTS
Establishment of BCC allografts
To establish murine BCC allografts, we harvested visible BCC
tumors from IR-treated Ptch1þ / mice in which p53 had
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been deleted specifically from keratin 14 (K14)-expressing
keratinocytes. We selected primary tumors with sizes ranging
from 100 to 400mm3, with no obvious ulceration or necrosis,
as we found that both factors reduce the recovery of viable
cells (data not shown), prepared single-cell suspensions from
the tumors with a typical yield of 0.5–5107 cells per tumor,
and injected NOD/SCID mice with 103 to 2 106 cells per
injection site subcutaneously. The average frequency of
tumor-initiating cells was 1:5.2 105 (L-calc, StemCell
Technologies). With our optimized protocol, in particular,
using collagenase to free tumor cells and injecting Matrigel
with the cells, we achieved 100% allograft growth when we
injected X106 cells. Injection of more than 106 cells
expedited the appearance of detectable tumors (3 weeks for
2106 vs. 5 weeks for 106) and enhanced the growth rate of
tumors once they became palpable (Figure 1b, t-test, paired,
Po0.001). We serially transplanted these primary allografts
twice before ending the experiments. Besides having a much
shorter tumor latency (3–5 weeks vs. 5 months), the allografts
grew significantly faster than autochthonous tumors did
(Figure 2a). In addition, the growth rate continued to increase
with further transplantation, i.e. tertiary transplants4second-
ary transplants4first transplants4primary tumors (Figure 2b).
Consistent with the augmented growth, allografts had a
higher percentage of Ki67-postive cells than did the primary
tumors (Figure 2c). The above data suggest that the number of
tumor-initiating cells may be enriched through in vivo
passaging of BCCs in NOD/SCID mice. At killing, we saw
no gross abnormality of lung, liver, or lymph nodes,
suggesting that, such as autochthonous BCCs, BCC allografts
did not metastasize.
We were also able to grow BSZ cells, one of our three
immortalized murine BCC cell lines (Aszterbaum et al., 1999;
So et al., 2006) tested, as allografts. We propagated the BSZ
cells as tumors in vivo for five passages before ending the
experiment, and found results similar to those with allografts
derived from primary tumors, i.e. short tumor latency,
increased growth rate, and lack of metastasis (data not
shown), despite the cell line having been passaged previously
for a decade.
Comparison of BCC allografts with the primary tumors from
which they were established
We have found that visible BCCs developing from IR-treated
Ptch1þ / mice with K14-specific deletion of p53 are of two
histological subtypes: Type I BCCs with branching and
radiating tumor cells, reminiscent of follicular differentiation,
some of which contain smooth muscle actin, and Type II
BCCs with basaloid cells arrayed in nests not resembling
follicular differentiation and lacking expression of tumor cell
smooth muscle actin (Mancuso et al., 2006; Wang et al.,
2011). Interestingly, we found that the allografts established
from tumors of each subtype retained the type I or type II
classification of the tumors from which they arose, indicating
that the histological subtype is an intrinsic characteristic of
these cells (Figure 3).
Next, we compared the immunohistological phenotypes
of the allografts with their parental tumors, assaying for the
basal keratinocyte marker K14, proliferation (Ki67),
vasculature (CD31), stromal distribution (collagen IV), and
HH signaling activity (Gli1). As shown in Figure 4, both the
allografts and their parental counterparts expressed K14
robustly, consistent with their keratinocyte cell of origin. It
has been reported that orthotopic ductal pancreatic cancer
autografts and xenografts have greater vascularity and a
shorter distance between blood vessels and tumor cells than
do the autochthonous tumors from which they are derived
(Olive et al., 2009). However, our BCC allografts had a
density and distribution of CD31þ blood vessels and stroma
surrounding tumors histologically similar to that of their
primary counterparts. To identify the origin of the stromal
cells, we probed allografts derived from primary tumors of
male mice grown in female NOD/SCID mice using a
Y-chromosome-specific probe. Stromal cells were identified
by lack of K14 staining. As shown in Figure 5, the allografts
and primary tumors had a similar percentage of Y-chromo-
some-labeled stromal cells, indicating that some, if not all, of
the stromal cells in direct allografts were from the original
tumors.
Murine BCCs driven by transgenic Gli2 expression need
continuous HH signaling to maintain tumor growth (Hutchin
et al., 2005). Therefore, we next measured mRNA levels of
Gli1, a well-established readout of HH signaling, in
autochthonous tumors, direct allografts, and in the estab-
lished BCC cell line (BSZ) grown both in vitro and in
allografts (Figure 6). Primary, autochthonous BCCs have the
highest levels of Gli1 mRNA expression, and the levels are
much (B22 fold) lower in the BSZ cells grown in vitro.
However, growth of the autochthonous tumor cells as
allografts reduced their Gli1 mRNA levels and growth of
the BSZ cells as allografts elevated their Gli1 mRNA levels so
that the Gli1 levels did not differ significantly between
allografts grown from the two sources.
Tazarotene inhibits BCC allograft growth
As the BCC allografts histopathologically reproduce their
primary tumors and grow significantly faster with shorter
tumor latency than the autochthonous tumors, they poten-
tially provide a model for screening anti-BCC drugs more
rapidly. As a proof of principle, we tested the effects on
allografts of oral tazarotene, whose topical applications
strongly inhibit autochthonous Ptch1þ / murine BCC
carcinogenesis (So et al., 2004, 2008). For this, we pooled
three BCC tumors from IR-treated Ptch1þ / K14CreER2
p53fl/fl mice, injected single-cell suspensions into two sites
per NOD/SCID mouse, and divided the NOD/SCID mice
randomly into three groups: a prevention group receiving
tazarotene, starting on the same day as the tumor cells were
injected; a treatment group starting tazarotene when allograft
tumors became palpable; and a control group injected only
with tumor cells. As shown in Figure 7, 6 weeks of oral
tazarotene completely blocked the appearance of palpable
tumors in the prevention group and markedly inhibited the
growth of palpable tumors in the treatment group (Figure 7,
P¼0.04 and 0.03). By the end of the initial 6-week
administration of 10mg kg1 at 5 days per week, body
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Figure 1. The growth rate of the allografts was dose-dependent. (a) The tumor volumes were significantly different between the two doses for week 5 (3.7±2.5
vs. 30.59±8.4, Po0.05), week 7, and week 9 (Po0.05, noted with *). According to the mouse protocol, all the mice that were injected with 2 106 cells were
killed at week 9 because of oversized tumors. (b) The specific growth rate (calculated by ln(V2)ln(V1)) of the allografts injected with 2 106 cells was
significantly higher than that of allografts injected with 106 cells. Data shown are average±SEM, n¼ 6 for each group.
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Figure 2. Tumor growth rate increased through serial in vivo passaging. (a) The tumor volumes were plotted against the weeks past since the appearance
of the first palpable tumor (defined as week 0). Data shown are average±SEM, n¼ 5 for each group. (b) P-values of t-test between groups are shown.
(c) Representative images show that there were more Ki67-positive cells in allografts than in the primary tumors. Bar¼20 mm.
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weights had decreased significantly in the prevention and
treatment groups, but not in the control group, indicating that
this dose was toxic. Therefore, we reduced the dose to
2mg kg1, and treated the mice for another 5 weeks. At this
lower dose, the drug-treated mice regained their body
weights to levels similar to those of the control mice, whereas
the tumor volumes of the treatment and prevention groups
remained significantly smaller than those of the control
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Figure 3. The allografts inherited the histopathological features of their original tumors. The allografts and their parental tumors were stained with hematoxylin
and eosin (H&E) or anti-smooth muscle actin (SMA) antibody and assessed for type I (characterized by branching and radiating tumor cells, SMA-positive)
or type II (characterized by basaloid cells arrayed in nests, SMA-negative) classification. Four primary tumors (two for each type) and the allografts derived
from them (n¼ 4 for each primary tumor) were analyzed. Bars¼50 mm.
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Figure 4. The allografts reproduced the immunophenotypic features of their original tumors. The allografts and their parental tumors were stained with anti-
K14, anti-collagen IV, and anti-CD31 antibodies to assess the basal keratinocyte cell of origin, stroma density, and vasculature properties. Bars¼ 50 mm.
K14, keratin 14.
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group. As expected, tumors in the prevention group were
significantly smaller than those of the treatment group over
the total 11-week exposure to tazarotene (Po0.05) (Figure 7,
inset). In fact, in the prevention group, 6 out of the 10
allografts remained impalpable until week 12, after tazar-
otene was stopped. We found previously that new auto-
chthonous microscopic BCCs in Ptch1þ / mice did not
appear when tazarotene was applied topically for 5 months
and then withdrawn for 5 months (So et al., 2008). By
contrast, when oral tazarotene was stopped, the previously
non-palpable allograft tumors became palpable within 2
weeks, and the existing tumors grew larger. The resumed
tumor growth was observed for allografts in both treatment
and prevention group. When we re-started administration of
tazarotene at 2mg kg1 per day in the treatment and
prevention groups after a 4-week tazarotene ‘‘drug-free
holiday’’, the BCC allografts still responded to tazarotene
with a 20–40% tumor volume reduction. These data indicate
that oral tazarotene suppresses the growth of BCC allografts
but does not eradicate the tumor cells, at least not using the
drug administration regimen tested here.
DISCUSSION
Despite technical advances, human BCCs have remained
difficult to culture in vitro as established cell lines or to
propagate in vivo as xenografts. Here, we report a method to
generate tumor allografts from IR-induced BCCs of Ptch1þ /
p53/ mice, a potent mouse tumor model with essentially
defined genetics, and representing the clinical scenario
(Aszterbaum et al., 1999). In contrast to the previous
attempts, the allografts showed a markedly increased engraft-
ment rate and reproduced their parental autochthonous tumors,
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Figure 5. The stromal cells from the original mouse were detected in direct
allografts. Primary basal cell carcinomas (BCCs) generated from male mouse
were injected into female NOD/SCID mice. Fluorescence in situ
hybridization was performed to detect cells from male donor mice with
Cy3-conjugated Y-chromosome-specific painting probe (red). BCC tumor
cells were stained with keratin 14 (K14) antibody (green). Y-chromosome-
positive and K14-negative stromal cells were identified (arrows).
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Figure 6. Hedgehog signaling activity. (a) Gene expression level of Gli1 was
determined by quantitative PCR for primary basal cell carcinomas (BCCs)
(n¼14), direct allografts (n¼ 9), BSZ cells (n¼ 3), and BSZ allografts (n¼ 9).
Y axis: fold changes (normalized by b-actin endogenous control) for each
assay. Identical thresholds of 0.2 were set for all runs with four technical
replicates. Data shown are average±SEM. (b) P-values of statistical analysis
between groups by t-test.
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in terms, of the histological and immunophenotypic features,
as well as response to the anti-BCC effects of tazarotene.
Several differences between our method and those
reported in previous studies may be the critical factors
underlying our success. First, the nude mice used in most
BCC xenograft studies lack functional T cells, but have B cells
and natural killer cells; NOD/SCID mice also have complete
loss of functional B cells and partial loss of macrophage
function and natural killer cell activity. It has become clear
that the immune microenvironment significantly affects the
frequency of tumor uptake. The more severe the immunode-
ficiency is, the more tolerant the host environment becomes,
thus allowing greater rate of tumor formation. In NOD/SCID
IL2Rgnull mice, which lack the residual natural killer cell
activity of NOD/SCID mice, even a single melanoma cell can
form a tumor (Quintana et al., 2008). Second, the usage of
Matrigel, a reconstituted biologically active basement mem-
brane-attachment matrix, may enhance the engraftment rate.
Matrigel is comprised of laminin, collagen IV, heparan sulfate
proteoglycan, and entactin, and has been reported to increase
the rate of tumor formation and shorten the tumor latency of
several tumor types, including small-cell lung cancer, renal
cell, and prostate carcinoma (Fridman et al., 1990, 1991;
Pretlow et al., 1991). Finally, we used mouse allografts versus
the human xenografts. It is well-recognized that xenografts
cause more powerful immune responses than allografts, as
they offer more foreign antigens as targets for an immune
response, and the rejection mechanisms are more vigorous in
xenogeneic than in allogeneic transplantation.
Our data differ in some respects from those generated by
similar studies of allografts of murine medulloblastomas
(Sasai et al., 2006). Both BCCs and medulloblastomas have
higher Gli1 expression in autochthonous tumors than in cell
lines established from those tumors, but we found down-
regulation of HH signaling in direct allografts of BCCs. By
contrast, direct allografts of medulloblastomas retained their
high levels of Gli1 mRNA expression. Furthermore, our cell
line expressed increased Gli1 mRNA levels as well as Ptch1
promoter activity (as assessed by b-galactosidase activity)
when transferred from in vitro to in vivo conditions; their
medulloblastoma cells lines had similar low Gli1 mRNA
levels in vitro and in vivo. The above discrepancy may simply
be a cancer-type-specific phenomenon. In the case of BCCs,
our findings highlight the substantial influence of tumor micro-
environment on HH activity, which may favor the growth of
tumor cells in the ‘‘new’’ host. Therefore, our allograft model
offers an excellent system to study the tumor micro-
environment, in particular, stromal–tumor cell interactions.
BCC cells are embedded in a dense stroma, which is
composed of fibroblasts (cancer-associated fibroblasts), en-
dothelial cells, inflammatory cells, and abundant extracel-
lular matrix. Collectively, these components provide a
favorable microenvironment to promote the survival of
cancer cells in both primary and metastatic sites (Liotta and
Kohn, 2001). Previous studies reported that the stromal cells
surrounding human BCC xenografts contained a mixture of
cells from both original tumors (human) and host animal
(mouse) (Grimwood et al., 1986; Stamp et al., 1988; Hales
et al., 1989). Our data also showed that some, if not all, of the
stromal cells in the allografts were from the donor mouse,
implying that these stromal cells, probably cancer-associated
fibroblasts, are indispensable for the growth of these
allografts.
Tazarotene-treated Ptch1þ / mice remained free of
visible tumors when tazarotene was discontinued after
5 months of topical treatment (So et al., 2008). By contrast,
the growth of allografts resumed rapidly once tazarotene was
withdrawn. This discrepancy could be due to the fact that the
previous experiments studied the effect of tazarotene on
microscopic BCCs; however, our allografts were derived from
macroscopic tumors, and retinoids are thought to be more
effective against early growths. In addition, we used BCCs
developed from p53/ keratinocytes, which are the more
aggressive type, in the present study as compared with BCCs
arising in p53þ /þ mice in the previous experiments. We are
in the process of establishing allografts from p53þ /þ BCCs
and xenografts from human BCCs and evaluating their
response to anti-BCC or anti-HH agents.
MATERIALS AND METHODS
Mice
Female NOD/SCID mice were purchased from Jackson laboratory
(stock number 001303, Sacramento, CA). Ptch1þ / K14-Cre-ER2
p53fl/fl mice were produced and used to develop BCC tumors
(Wang et al., 2011). All mice were housed under standard conditions
(fluorescent lighting 12hours per day, room temperature 23–25 1C,
and relative humidity 45–55%). Animal care and use were in
compliance with the protocols approved by the Institutional Animal
Care and Use Committee of Children’s Hospital Oakland Research
Institute.
7,000
30
25
20
15
10
0
010
5
3
32
2 2
Weeks past
1
4 5
P<0.05
Av
e
ra
ge
 tu
m
or
 vo
lu
m
e
6 7 8 9 10 11
4 5 6 7 8 9 10 11 12 13 14 15 16 17 18
6,000
5,000
4,000
3,000 Control
Treatment
Prevention2,000
1,000
0
Tazarotene
mg kg –1
Av
e
ra
ge
 tu
m
or
 vo
lu
m
e 
(m
m3
)
Figure 7. Basal cell carcinoma allografts responded to tazarotene treatment.
The allografts were randomly divided into three groups: the prevention group
(n¼10) received tazarotene when tumor cells were injected (defined as
week 0); treatment group (n¼10) received tazarotene once palpable tumors
were observed (i.e., week 3); and the control group (n¼ 8) received no
treatment. Tumor volumes (measured once a week) are plotted against weeks
past. Inset: prevention and treatment groups are plotted with a small scale
of Y axis for tazarotene exposure period of week 3–week 11. It appeared
that the treatment group grew significantly faster than the prevention group
(t-test, paired, Po0.05). Data shown are average±SEM.
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Preparation of tumor cell suspension
Tumors were collected aseptically from donor mice and briefly
incubated in penicillin/streptomycin (UCSF cell culture facility, San
Francisco, CA) with two changes of solution. After removing the
surrounding skin, the tumors were minced, followed by digestion
with 0.25% trypsin (UCSF cell culture facility), 25Uml1 of dispase
(Invitrogen, Carlsbad, CA) or collagenase type I (Invitrogen) at 4 1C
overnight. As digestion with collagenase type I generally gave the
optimal results, i.e. higher yield and better cell viability, we prepared
all tumor cell suspensions with this method for the following
experiments. The cell suspensions were diluted with DMEM
containing 10% chelexed fetal bovine serum (calcium-free) and
filtered through 70mm cell strainers (BD Biosciences, Bedford, MA).
After washing twice with DPBS (calcium-free PBS), viable cell
counts were determined using 0.4% trypan blue and desired cell
concentration were prepared in DPBS.
Injection of tumor cell suspensions and assessment of tumor
growth
Tumor cell suspensions were mixed 1:1 with Matrigel (BD
Biosciences) and injected subcutaneously into the left and right
lateral sides of NOD/SCID mice with five mice per group. Tumor
growth was monitored weekly, and tumor volume was calculated
according to the ellipsoid volume formula (p/6 LWH ).
Immunostaining and quantitative PCR
Tumor fixation, b-galactosidase staining, hemotoxylin and eosin
stain, and immunohistochemistry were carried out as described
previously (Wang et al., 2011). Briefly, rehydrated samples were
subjected to antigen retrieval with rodent decloaker (Biocare
Medical, Concord, CA) for 10–20minutes at 95–1000 1C, followed
by incubation with rodent block M (Biocare Medical) for 15minutes,
primary antibody for 1 hour at room temperature or 4 1C
overnight with the following primary antibodies: Ki67 (1:400;
Thermo Scientific, Fremont, CA), K14 (1:1,000; Covance, Princeton,
NJ), collagen IV (1:1,000; Abcam, Cambridge, MA), CD31 (1:50;
Abcam), Gli1 (1:1,000; Rockland, Gilbertsville, PA). Rabbit
on rodent HRP-polymer was used as secondary antibody and
incubated for 20minutes (Biocare Medical). Signal was developed
using liquid DABþ substrate (Dako, Carpinteria, CA) for 2–5min-
utes and counterstained with Cat hematoxylin (Biocare
Medical).
For quantitative PCR, total RNA was prepared using either Trizol
(Invitrogen) or QuickGene RNA tissue kit SII (Fujifilm, Life Science,
Tokyo, Japan) according to the manufacturer’s instruction. Quanti-
tative PCR reactions were carried out using the TaqMan Real-time
PCR system (Applied Biosystems, Foster City, CA) after reverse
transcribing total RNA into cDNA using a high-capacity RNA-to-
cDNA kit (Applied Biosystems). The TaqMan gene expression assay
for Gli1 was purchased (Applied Biosystems).
Fluorescence in situ hybridization
Fluorescence in situ hybridization was performed with Cy3-
conjugated mouse Y-chromosome-specific painting probe according
to the manufacturer’s protocol (Cambio, Cambridge, UK) with the
following modifications: (1) pepsin digestion step was replaced with
proteinase K (digest-All 4, Invitrogen) incubation at room tempera-
ture for 1–4minutes; (2) before mounting with DAPI/anti-fade
solution (Millipore, Billerica, MA), slides were stained with rabbit
polyclonal anti-K14 antibody (1:1,000, Covance) followed by
incubation with Alexa Fluor 488-conjugated anti-rabbit secondary
antibody (1:500, Molecular Probes, Invitrogen). Images were
acquired using LSM710 confocal microscope and processed with
Zeiss Zen software (Carl Zeiss, Germany).
Systemic administration of tazarotene
Tazarotene (Allergan, Irvin, CA) was reconstituted in 100% ethanol
to give 100mgml1 stock, which was further diluted with sunflower
seed oil (Sigma-Aldrich, St Louis, MO) to get 1mgml1 of working
solution. Tazarotene was administered by oral gauvage to mice at
10 or 2mgkg1 with 20-gauge stainless steel, curved feeding needles
(Popper and Sons, New Hyde Park, NY), 5 days per week.
Statistical analyses
The frequency of tumor-initiating cells was determined using L-calc
software (StemCell Technologies, Vancouver, BC, Canada). The
difference in tumor growth rate between primary tumors and serial
transplants (first, secondary, and tertiary) was analyzed, with week
being the continuous variable to model the growth rate of change.
To assess the effect of tazarotene on allografts, tumor growth was
analyzed with a general linear model with repeated measures over
time. SAS System (version 9.2, Cary, NC) or Microsoft Excel was
used for the statistical analysis.
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